Xanax — Class II drug recall D-0161-2016
Terminated recall by Pfizer Inc., reported 2015-11-04, distributed nationwide. Subpotent Drug
| Recall number | D-0161-2016 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Pfizer Inc., New York, NY, United States |
| Recall initiated | 2015-09-24 |
| Classified | 2015-10-29 |
| Reported by FDA | 2015-11-04 |
| Terminated | 2017-05-08 |
| Distributed | Nationwide (US) |
| Quantity | 21,120 hdpe |
| Reason classes | potency |
| NDC | 00009-0029, 00009-0029-01, 00009-0029-02, 00009-0029-14, 00009-0029-46, 00009-0055, 00009-0055-01, 00009-0055-03, 00009-0055-15, 00009-0055-46, 00009-0090, 00009-0090-01, 00009-0090-04, 00009-0090-13, 00009-0094, 00009-0094-01, 00009-0094-03 |
| Lot numbers | 02/16, C111054 |
Product
Xanax (alprazolam) tablets, 0.25 mg, 100-count bottle, Rx only, Distributed by Pharmacia & Upjohn Co. Division of Pfizer Inc, NY, NY 10017, NDC 0009-0029-01
Reason for recall
Subpotent Drug
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0161-2016. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.